scholarly journals Systemic Lupus Erythematosus and implications for the oral cavity

2020 ◽  
Vol 3 (9) ◽  
pp. 444-453
Author(s):  
Inês Lopes Cardoso ◽  
M. Fernanda C. Leal ◽  
Renan C. D. Regis
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Oral Cavity ◽  
Inflammatory Disease ◽  
Lupus Erythematosus ◽  
Chronic Inflammatory Disease ◽  
Systemic Lupus ◽  
Early Signs ◽  
The World

Systemic Lupus Erythematosus affects several people around the world and because it is characterized as a chronic inflammatory disease of multifactorial origin, and with systemic impairment, great attention must be paid from diagnosis to treatment in order to optimize the entire follow-up of the patient. The dental doctor plays an important role in the diagnosis of the condition and must be attentive to the early signs that can appear in the oral cavity with a frequency of up to 21%. In this way, through this bibliographic review, which has as main goal to correlate Systemic Lupus Erythematosus with its direct consequences in the oral cavity, it will be possible to help dentists in the diagnosis, to understand in detail the development of the disease and what attitude should be taken in its presence.

Malacoplakia of the Retroperitoneum in a Girl with Systemic Lupus Erythematosus

PEDIATRICS ◽  
1982 ◽  
Vol 70 (2) ◽  
pp. 296-299
Author(s):  
Jahed A. Hamdan ◽  
Mohammed S. Ahmad ◽  
Abdel Rahman Sa'adi
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Inflammatory Response ◽  
Inflammatory Disease ◽  
Lupus Erythematosus ◽  
English Language ◽  
Chronic Inflammatory Disease ◽  
Systemic Lupus ◽  
The Third ◽  
Language Literature

Malacoplakia is a rare chronic inflammatory disease, usually involving the bladder but occasionally affecting other organs. However, only two cases of malacoplakia of the retroperitoneum and ureter have been reported in the English language literature.1,2 Herein, we describe the third case of malacoplakia of the retroperitoneum and ureter in a patient with systemic lupus erythematosus who had been receiving prednisone therapy for two years. Modification by the steroid of phagocytosis and of the normal inflammatory response to bacterial infection, and the systemic lupus erythematosus, may have been of major importance in the genesis of malacoplakia in this patient. CASE REPORT

scholarly journals Cricoarytenoiditis as an Initial Manifestation of Systemic Lupus Erythematosus

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Jean-Michel Hougardy ◽  
Nicolas Roper ◽  
Alain Michils ◽  
Muhammad S. Soyfoo
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Inflammatory Disease ◽  
Lupus Erythematosus ◽  
Clinical Manifestations ◽  
Chronic Inflammatory Disease ◽  
Vocal Cord Dysfunction ◽  
Systemic Lupus ◽  
Vocal Cords ◽  
Initial Manifestation ◽  
Life Threatening

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease encompassing a broadened spectrum of clinical manifestations. Vocal cords involvement in SLE is not a frequent entity but can be life threatening if not treated. We hereby report the case of a patient presenting with cricoarytenoiditis and vocal cord dysfunction revealing SLE.

scholarly journals Clinical Profile of Patients with Systemic Lupus Erythematosus

2012 ◽  
Vol 52 (187) ◽  
Author(s):  
B Paudyal ◽  
M Gyawalee
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibody ◽  
Clinical Profile ◽  
International Studies ◽  
Systemic Lupus ◽  
Cutaneous Manifestations ◽  
American College Of Rheumatology ◽  
The World

Introduction: Clinical features of Systemic lupus erythematosus vary between different parts of the World; however, this information on Nepalese Sytemic lupus erythematosus does not exist. Methods: Patients with Systemic lupus erythematosus fulfilling the American College of Rheumatology criteria treated in Patan Hospital were studied by means of retrospective review of their case records. The results were compared with various regional and international studies. Results: The female to male ratio was 36:1 with a mean age at diagnosis 28.67 years. Cutaneous manifestations were the most common 72 (96%) presentations followed by musculoskeletal involvement 70 (93%). Haematological and renal involvements each were present in 33 (44%) of patients. Pulmonary and neuropsychiatric involvements were present in 15 (20%) and 8 (11%) patients respectively. Antinuclear antibody and anti-double stranded deoxyribonucleic acid antibodies were positive in 70 (93%) and 66 (88%) of patients respectively. A quarter of patients had some form of co-morbid conditions. At the time of last follow up, 70 (93%), 66 (90%), and 6 (9%) of patients were taking antimalarials, steroids and immunosuppressive agentsrespectively, mostly in combinations. Eighty seven percent of patients had their disease activity under control at the time of last follow up whereas four percent still had an active disease. In another four percent died during the course of therapy and the outcome was unknown in another four percent of patients who lost to follow up. Conclusions: Clinical characteristics and antinuclear antibody pattern of Nepalese lupus patients is more or less similar to those with patients from other countries in the region and in the World. Keywords: clinical profile; Nepal; systemic lupus erythematosus.

scholarly journals Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Danielle Perez-Bercoff ◽  
Hélène Laude ◽  
Morgane Lemaire ◽  
Oliver Hunewald ◽  
Valérie Thiers ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cell Death ◽  
Lupus Erythematosus ◽  
Immunosuppressive Treatment ◽  
Elevated Serum ◽  
Serum Levels ◽  
Chronic Inflammatory Disease ◽  
Mrna Levels ◽  
Systemic Lupus ◽  
Inflammatory Conditions

AbstractAPOBEC3 (A3) enzymes are best known for their role as antiviral restriction factors and as mutagens in cancer. Although four of them, A3A, A3B, A3F and A3G, are induced by type-1-interferon (IFN-I), their role in inflammatory conditions is unknown. We thus investigated the expression of A3, and particularly A3A and A3B because of their ability to edit cellular DNA, in Systemic Lupus Erythematosus (SLE), a chronic inflammatory disease characterized by high IFN-α serum levels. In a cohort of 57 SLE patients, A3A and A3B, but also A3C and A3G, were upregulated ~ 10 to 15-fold (> 1000-fold for A3B) compared to healthy controls, particularly in patients with flares and elevated serum IFN-α levels. Hydroxychloroquine, corticosteroids and immunosuppressive treatment did not reverse A3 levels. The A3AΔ3B polymorphism, which potentiates A3A, was detected in 14.9% of patients and in 10% of controls, and was associated with higher A3A mRNA expression. A3A and A3B mRNA levels, but not A3C or A3G, were correlated positively with dsDNA breaks and negatively with lymphopenia. Exposure of SLE PBMCs to IFN-α in culture induced massive and sustained A3A levels by 4 h and led to massive cell death. Furthermore, the rs2853669 A > G polymorphism in the telomerase reverse transcriptase (TERT) promoter, which disrupts an Ets-TCF-binding site and influences certain cancers, was highly prevalent in SLE patients, possibly contributing to lymphopenia. Taken together, these findings suggest that high baseline A3A and A3B levels may contribute to cell frailty, lymphopenia and to the generation of neoantigens in SLE patients. Targeting A3 expression could be a strategy to reverse cell death and the generation of neoantigens.

Occasional Series: Lupus Around the World Systemic lupus erythematosus in São Paulo/Brazil: a clinical and laboratory overview

Lupus ◽  
1995 ◽  
Vol 4 (2) ◽  
pp. 100-103 ◽  
Author(s):  
WH Chahade ◽  
EI Sato ◽  
JE Moura ◽  
Ltl Costallat ◽  
Lec Andrade
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Sao Paulo ◽  
São Paulo ◽  
Systemic Lupus ◽  
The World

Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients

2014 ◽  
Vol 26 (2) ◽  
pp. 459-467 ◽  
Author(s):  
L. P. C. Seguro ◽  
C. B. Casella ◽  
V. F. Caparbo ◽  
R. M. Oliveira ◽  
A. Bonfa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Bone Loss ◽  
Lupus Erythematosus ◽  
Predictive Marker ◽  
Serum Levels ◽  
Systemic Lupus

scholarly journals The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Liuye Huang ◽  
Yuan Yang ◽  
Yu Kuang ◽  
Dapeng Wei ◽  
Wanyi Li ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
T Cell ◽  
Side Effects ◽  
Lupus Erythematosus ◽  
Clinical Symptoms ◽  
Systemic Lupus ◽  
T Cell Vaccination ◽  
Dna Antibodies

Objective. Systemic lupus erythematosus (SLE) is an autoimmune disease identified by a plethora of production of autoantibodies. Autoreactive T cells may play an important role in the process. Attenuated T cell vaccination (TCV) has proven to benefit some autoimmune diseases by deleting or suppressing pathogenic T cells. However, clinical evidence for TCV in SLE is still limited. Therefore, this self-controlled study concentrates on the clinical effects of TCV on SLE patients. Methods. 16 patients were enrolled in the study; they accepted TCV regularly. SLEDAI, clinical symptoms, blood parameters including complements 3 and 4 levels, ANA, and anti-ds-DNA antibodies were tested. In addition, the side effects and drug usage were observed during the patients’ treatment and follow-up. Results. Remissions in clinical symptoms such as facial rash, vasculitis, and proteinuria were noted in most patients. There are also evident reductions in SLEDAI, anti-ds-DNA antibodies, and GC dose and increases in C3 and C4 levels, with no pathogenic side effects during treatment and follow-up. Conclusions. T cell vaccination is helpful in alleviating and regulating systemic lupus erythematosus manifestation.

scholarly journals Chorea as a First Manifestation in Young Patients with Systemic Lupus Erythematosus who Was Initially Diagnosed with Rheumatic Fever

2012 ◽  
Vol 5 ◽  
pp. CCRep.S9143 ◽  
Author(s):  
Jamal A Albishri
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Rheumatic Fever ◽  
Lupus Erythematosus ◽  
Young Patients ◽  
Systemic Lupus ◽  
Incorrect Diagnosis ◽  
Rare Manifestation ◽  
Specific Increase ◽  
Anti Phospholipid Syndrome

Chorea is a rare manifestation of systemic lupus erythematosus (SLE). We report on a young patient with chorea who was diagnosed initially with rheumatic fever. Follow up and further evaluation confirmed the diagnosis of SLE and anti-phospholipid syndrome. Of special interest were the negative antiphospholipid (aPL) antibodies and the initial diagnosis of rheumatic fever which is still not uncommon problem in our region. The rarity of such presentation with joint and non specific increase of antistreptolysin O (ASO) titer might be the factors that led to an incorrect diagnosis. Early diagnosis and treatment of SLE and anti-phospholipid syndrome are very crucial and should be considered with such presentation.

Occasional Series—Lupus Around the World Systemic lupus erythematosus in India

Lupus ◽  
1997 ◽  
Vol 6 (9) ◽  
pp. 690-700 ◽  
Author(s):  
AN Malaviya ◽  
AN Chandrasekaran ◽  
A. Kumar ◽  
PN Shamar
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
The World
Sign in / Sign up

Export Citation Format

Share Document